Global Incidence of Multiple Myeloma on the Rise
The global incidence of multiple myeloma is on the rise, particularly among men, people 50 years of age or older, and those from high-income countries.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
Certain Blood Cancer Patients Do Not Seroconvert After a Third COVID-19 Vaccine Dose
Seroconversion rates were low for patients receiving anti-CD20 therapy, CAR T-cell therapy, and transplants, as well as CLL patients taking ibrutinib. -
Measuring Circulating Tumor Cells at Diagnosis Can Improve Risk Stratification in Multiple Myeloma
Circulating tumor cell levels were an independent predictor of progression-free survival and overall survival. -
Data Support Daratumumab for Transplant-Eligible, Newly Diagnosed Multiple Myeloma
Final results from the GRIFFIN trial support adding daratumumab to induction, consolidation, and maintenance therapy for patients with newly diagnosed, transplant-eligible multiple myeloma. -
Clinical Trials Not Representative of Population With Leukemia, Multiple Myeloma
Women were underrepresented in AML trials, and men were underrepresented in MM and CML trials.
MULTIPLE MYELOMA NEWS
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Isatuximab Plus RVd Dubbed New Standard Care in Newly Diagnosed Multiple Myeloma
T-Cell Engaging Therapies Show Promise as Salvage After CAR-T Therapy in MM
Older MM Patients Have More Advanced Disease, Worse Outcomes in Real World vs RCTs
Cilta-Cel May Fulfill Unmet Need for Multiple Myeloma Patients in China
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
Loading... 
Loading...